• Hawbir Ahmed Gharib Zhianawa Cancer Center, Sulaimani, Kurdistan Region, Iraq.
  • Ari Sami Hussain Nadhim College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
  • Bamo Mohammed Muhsin College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.



High-Grade Glioma, Glioblastoma, Clinical characteristics, Survival, Prognostic factors


The prognosis for glioma patients is poor, despite recent advances in diagnosis and treatment. Understanding Glioma’s clinical characteristics and predictive factors is crucial for patient treatment and management.

To assess the survival duration of HGG patients at a single facility and to discover clinical determinants of treatment outcome in HGG treated with a combined modality approach in Zhianawa Cancer Center.

Patients and Methods
This study included 133 patients with high-grade gliomas diagnosed between January 2015 and January 2020; these patients were referred to the Zhianawa Cancer Center. A retrospective analysis of the clinical data included survival outcomes, tumour characteristics, and demographic information. While the Cox regression model was used for the evaluation of multivariate data to look at the risk factors for mortality, on the other hand, survival data were analyzed using Kaplan-Meier curves with a log-rank test.

In this particular patient cohort, grade IV glioma (83.9%), grade III glioma  (16.1), and glioblastoma  (81.4%) were the most common pathological types. A poor prognosis was associated with not using temozolomide, having a Karnofsky Performance Score (KPS) of less than 70%, and not receiving radiotherapy. Univariate analysis showed low KPS (70) to increase the risk of mortality. Patients who had radiotherapy with normal fractionation, concurrent chemotherapy, and radiotherapy adjuvant chemotherapy had the highest overall survival rates.

Mortality was significantly related to aging, absence of seizures, presence of motor alteration, pathological grade IV gliosarcoma, glioblastoma multiform, and non-standard radiation dose.


Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary Brain and other central nervous system tumours diagnosed in the United States in 2011–2015. Neuro-Oncology. 2018;20(suppl_4):iv1–iv86. DOI:

de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, et al. The worldwide incidence and prevalence of primary brain tumours: a systematic review and meta-analysis. Neuro-Oncology. 2015;17(6):776–83. DOI:

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017. DOI:

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of central nervous system tumours: A summary. Acta Neuropathologica. 2016;131(6):803–20. DOI:

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 classification of tumours of the central nervous system. Acta Neuropathologica. 2007;114(2):97–109. DOI:

Johnson DR. Rising incidence of glioblastoma and meningioma in the United States: Projections through 2050. Journal of Clinical Oncology. 2012;30(15_suppl):2065. DOI:

Chen S, Tanaka S, Giannini C, Morris J, Yan ES, Buckner J, et al. Gliomatosis Cerebri: Clinical characteristics, management, and outcomes. Journal of Neuro-Oncology. 2013;112(2):267–75. DOI:

Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, BarnholtzSloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev. 2014;23(10):1985–96. DOI:

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med, 2005 352:987–96. DOI:

Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Norgard BM, et al. Epidemiology of Glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the Danish Neuro-oncology registry. J Neuro-Oncol. 2017;135(3):571–9. DOI:

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of Glioma in adults: A "State of the science" review. Neuro-Oncology. 2014;16(7):896–913. DOI:

Klein JP, Dietrich J. Neuroradiologic pearls for neuro-oncology. CONTINUUM: Lifelong Learning in Neurology. 2017;23(6):1619–34. DOI:

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009;10(5):459–66. DOI:

Hervey-Jumper SL, Berger MS. Role of surgical resection in low- and high-grade gliomas. Curr Treat Options Neurol 2014; 16(4):284. DOI:

Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, et al. Randomised comparisons of radiotherapy and Nitrosoureas for the treatment of malignant Glioma after surgery. New England Journal of Medicine. 1980;303(23):1323–9. DOI:

Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704‑10. DOI:

Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: A report of the prospective randomised EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology. 2015;18(3):388–400. DOI:

Lacroix M, Abi‑Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, the extent of resection, and survival. J Neurosurg 2001;95:190‑8. DOI:

Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant Glioma: Data from the Glioma Outcomes Project. J Neurosurg 2003;99:467‑73. DOI:

Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors. Neurol Clin 2018;36:395-419. DOI:

Khan S, Kambris ME, AlShamsi ET. Epidemiology of brain tumors in the United Arab Emirates: A national registry cross-sectional study. BMC Neurology. 2020;20(1). DOI:

Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. Journal of Neuro-Oncology. 2012;109(2):391–7. DOI:

Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, et al. Surgical outcomes for older patients with glioblastoma multiforme: Preoperative factors associated with decreased survival. Journal of Neurosurgery. 2011;114(3):587–94. DOI:

Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatric Blood Cancer. 2014;61(7):1173–9. DOI:

Lowry JK, Snyder JJ, Lowry PW. Brain tumours in the elderly: recent trends Minnesota cohort study. Arch Neurol. 1998;55(7):922–8. DOI:

Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, Barón AE, Yeh N, et al. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. Int J Radiat Oncol Biol Phys. 2014;90(4):894–902. DOI:

Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, et al. Association of the extent of resection with survival in glioblastoma. JAMA Oncology. 2016;2(11):1460. DOI:

McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62. DOI:

Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS, et al. Underutilisation of radiation therapy in patients with glioblastoma: Predictive factors and outcomes. Cancer. 2014;120(2):238–43. DOI:

van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre J-Y, et al. Adjuvant Procarbazine, Lomustine, and Vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology. 2013;31(3):344–50. DOI:

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, et al. NCCN guidelines insights: Central Nervous System Cancers, version 1.2017. Journal of the National Comprehensive Cancer Network. 2017;15(11):1331–45. DOI:

Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. Journal of Neurosurgery. 1993;78(5):767–75. DOI:

Bouffet E, Adamski J. Faculty opinions recommendation of CBTRUS Statistical Report: Primary brain and central nervous system tumours diagnosed in the United States in 2006-2010. Faculty Opinions–Post-Publication Peer Review of the Biomedical Literature. 2014; DOI:

Siangprasertkij, Chaiyot, and Yot Navalitloha. “A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.” Journal of the Medical Association of Thailand = Chotmaihet thangphaet vol. 91,4 (2008): 491-6.

Chansriwong P, Sirisinha T. Clinical features management and outcomes of high-grade glioma patients in Ramathibodi Hospital. J Med Assoc Thai 2010;93 Suppl 2:S68‑73.



How to Cite

Gharib H, Nadhim A, Muhsin B. SURVIVAL OUTCOMES AMONG PATIENTS WITH HIGH-GRADE GLIOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY. JSMC [Internet]. 2023 Sep. 21 [cited 2024 Jul. 15];13(3):11. Available from:

Similar Articles

1-10 of 267

You may also start an advanced similarity search for this article.